$367 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 51 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 60.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $28,514,000 | +24.5% | 1,627,500 | +5.3% | 7.76% | +24.7% |
| SAGE | Buy | SAGE THERAPEUTICS INC | $22,129,000 | +60.9% | 255,800 | +13.7% | 6.02% | +61.2% |
| KURA | Sell | KURA ONCOLOGY INC | $20,821,000 | -30.2% | 637,500 | -34.5% | 5.67% | -30.0% |
| LRMR | Buy | LARIMAR THERAPEUTICS INC | $18,479,000 | +46.8% | 863,100 | +4.0% | 5.03% | +47.1% |
| MRSN | Buy | MERSANA THERAPEUTICS INC | $18,467,000 | +48.6% | 694,000 | +4.0% | 5.02% | +48.9% |
| CMPS | Sell | COMPASS PATHWAYS PLCsponsored ads | $15,197,000 | +11.7% | 319,000 | -18.2% | 4.14% | +11.9% |
| VTGN | New | VISTAGEN THERAPEUTICS INC | $14,550,000 | – | 7,500,000 | +100.0% | 3.96% | – |
| ATHA | Buy | ATHIRA PHARMA INC | $13,460,000 | +101.1% | 393,000 | +8.4% | 3.66% | +101.6% |
| IMVT | Buy | IMMUNOVANT INC | $13,095,000 | +48.8% | 283,500 | +13.4% | 3.56% | +49.1% |
| Sell | TRILLIUM THERAPEUTICS INC | $11,812,000 | -2.5% | 803,000 | -5.9% | 3.21% | -2.4% | |
| ARWR | Buy | ARROWHEAD PHARMACEUTICALS IN | $10,665,000 | +144.0% | 139,000 | +36.9% | 2.90% | +144.5% |
| ETNB | Buy | 89BIO INC | $10,586,000 | -1.2% | 434,400 | +4.0% | 2.88% | -1.0% |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $10,353,000 | +191.4% | 465,500 | +93.4% | 2.82% | +191.9% |
| APLS | APELLIS PHARMACEUTICALS INC | $9,555,000 | +89.6% | 167,054 | 0.0% | 2.60% | +89.9% | |
| BLSA | New | BCLS ACQUISITION CORP | $9,385,000 | – | 842,500 | +100.0% | 2.55% | – |
| SURF | Sell | SURFACE ONCOLOGY INC | $9,235,000 | +23.0% | 999,500 | -8.1% | 2.51% | +23.2% |
| CBIO | Sell | CATALYST BIOSCIENCES INC | $8,566,000 | +33.0% | 1,357,500 | -9.4% | 2.33% | +33.3% |
| ISEE | Buy | IVERIC BIO INC | $8,378,000 | +85.1% | 1,212,500 | +51.1% | 2.28% | +85.5% |
| FULC | Buy | FULCRUM THERAPEUTICS INC | $7,992,000 | +164.2% | 682,500 | +78.9% | 2.18% | +164.6% |
| REPL | New | REPLIMUNE GROUP INC | $7,916,000 | – | 207,500 | +100.0% | 2.15% | – |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $7,647,000 | -26.3% | 164,800 | -47.7% | 2.08% | -26.1% |
| CNCE | Buy | CONCERT PHARMACEUTICALS INC | $6,794,000 | +130.6% | 537,500 | +79.2% | 1.85% | +131.1% |
| ALT | Sell | ALTIMMUNE INC | $6,525,000 | -28.2% | 578,500 | -15.9% | 1.78% | -28.0% |
| RNA | Buy | AVIDITY BIOSCIENCES INC | $6,283,000 | -5.0% | 246,200 | +4.8% | 1.71% | -4.8% |
| JYAC | New | JIYA ACQUISITION CORP | $5,794,000 | – | 562,500 | +100.0% | 1.58% | – |
| STOK | New | STOKE THERAPEUTICS INC | $5,729,000 | – | 92,500 | +100.0% | 1.56% | – |
| VSTM | VERASTEM INC | $5,112,000 | +76.0% | 2,400,000 | 0.0% | 1.39% | +76.3% | |
| HSAQ | HEALTH SCIENCES ACQ CORP 2 | $5,028,000 | +16.4% | 392,500 | 0.0% | 1.37% | +16.6% | |
| AVDL | AVADEL PHARMACEUTICALS PLCsponsored adr | $4,711,000 | +32.6% | 705,218 | 0.0% | 1.28% | +32.8% | |
| CRIS | New | CURIS INC | $4,341,000 | – | 530,000 | +100.0% | 1.18% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO Lcall | $4,286,000 | – | 50,000 | +100.0% | 1.17% | – |
| PRAX | New | PRAXIS PRECISION MEDICINES I | $4,162,000 | – | 75,645 | +100.0% | 1.13% | – |
| RAPT | Sell | RAPT THERAPEUTICS INC | $4,140,000 | -46.4% | 209,600 | -12.7% | 1.13% | -46.3% |
| RLMD | Sell | RELMADA THERAPEUTICS INC | $3,848,000 | -63.1% | 120,000 | -56.7% | 1.05% | -63.0% |
| CCCC | New | C4 THERAPEUTICS INC | $3,644,000 | – | 110,000 | +100.0% | 0.99% | – |
| MDGL | New | MADRIGAL PHARMACEUTICALS INC | $3,613,000 | – | 32,500 | +100.0% | 0.98% | – |
| CLSD | Buy | CLEARSIDE BIOMEDICAL INC | $3,425,000 | +261.7% | 1,250,000 | +103.3% | 0.93% | +262.6% |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $1,894,000 | -65.8% | 330,000 | -56.9% | 0.52% | -65.8% |
| ONCR | New | ONCORUS INC | $1,730,000 | – | 53,500 | +100.0% | 0.47% | – |
| ALDX | Sell | ALDEYRA THERAPEUTICS INC | $1,321,000 | -89.2% | 192,500 | -88.3% | 0.36% | -89.2% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $1,230,000 | -63.0% | 80,000 | -73.3% | 0.34% | -62.9% |
| CYCC | New | CYCLACEL PHARMACEUTICALS INC | $1,172,000 | – | 150,000 | +100.0% | 0.32% | – |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $1,097,000 | – | 20,000 | +100.0% | 0.30% | – |
| PMVP | New | PMV PHARMACEUTICALS INC | $923,000 | – | 15,000 | +100.0% | 0.25% | – |
| WVE | WAVE LIFE SCIENCES LTD | $846,000 | -7.3% | 107,500 | 0.0% | 0.23% | -7.3% | |
| FDMT | New | 4D MOLECULAR THERAPEUTICS IN | $829,000 | – | 20,000 | +100.0% | 0.23% | – |
| ANNX | Sell | ANNEXON INC | $626,000 | -81.2% | 25,000 | -77.3% | 0.17% | -81.2% |
| KRTX | Sell | KARUNA THERAPEUTICS INC | $508,000 | -51.3% | 5,000 | -63.0% | 0.14% | -51.4% |
| AXSM | Sell | AXSOME THERAPEUTICS INC | $489,000 | -69.5% | 6,000 | -73.3% | 0.13% | -69.4% |
| PANAWS | New | PANACEA ACQUISITION CORP*w exp 07/07/202 | $299,000 | – | 93,332 | +100.0% | 0.08% | – |
| NVAX | New | NOVAVAX INC | $279,000 | – | 2,500 | +100.0% | 0.08% | – |
| UMRX | Exit | UNUM THERAPEUTICS INC | $0 | – | -410,000 | -100.0% | -0.26% | – |
| BCRX | Exit | BIOCRYST PHARMACEUTICALS | $0 | – | -660,000 | -100.0% | -0.62% | – |
| PANAU | Exit | PANACEA ACQUISITION CORPunit 99/99/9999 | $0 | – | -280,000 | -100.0% | -0.91% | – |
| CRDF | Exit | CARDIFF ONCOLOGY INC | $0 | – | -305,900 | -100.0% | -1.18% | – |
| SELB | Exit | SELECTA BIOSCIENCES INC | $0 | – | -2,364,204 | -100.0% | -1.59% | – |
| LSACU | Exit | LIFESCI ACQUISITION CORPunit 03/31/2025 | $0 | – | -560,000 | -100.0% | -2.07% | – |
| CYTK | Exit | CYTOKINETICS INC | $0 | – | -357,500 | -100.0% | -2.10% | – |
| XBI | Exit | SPDR SER TRput | $0 | – | -250,000 | -100.0% | -7.57% | – |
| IMMU | Exit | IMMUNOMEDICS INC | $0 | – | -511,500 | -100.0% | -11.81% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.